DRAWINGS

Fig. 1




Fig. 2




Fig. 3



AST(IU/L)
25,000
20,000
15,000
10,000
5,000
0
G1 G2 G3
ALT(IU/L)
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
G1 G2 G3

Fig. 4



AST(IU/L)
6,000
4,000
2,000
0
G1 G2
ALT(IU/L)
6,000
4,000
2,000
0
G1 G2

Fig. 5



AST(IU/L)
16,000
12,000
8,000
4,000
0
G1 G2 G3
ALT(IU/L)
12,500
10,000
7,500
5,000
2,500
0
G1 G2 G3

Fig. 6




AST(U/L)
1,250
1,000
750
500
250
0
G1 G2 G3
ALT(U/L)
3,000
2,000
1,000
0
G1 G2 G3

Fig. 7

A


Fibrosis Score
4
3
2
1
0
Normal
10%
10%+MSC
25%
25%+MSC

B



Hydroxyproline content in liver tissue
(μg/g liver)
5000
4000
3000
2000
1000
0
Normal
10%
10%+MSC
25%
25%+MSC

Fig. 8



Hydroxyproline(μg/gLiver)
200
150
100
50
0
normal
CCl4
CCl4+MSC

Fig. 9



Hydroxyproline (μg/gLiver)
600
500
400
300
200
100
0
Normal
NASH
NASH + MSC

Fig. 10




1,200
1,000
800
600
400
200
0
HYP concentration
(μg/g liver)
Normal
Vehicle control
hADSC (TRB02) Single administration
hADSC (TRB03) Single administration
hADSC (TRB03) Biweekly administration 4 times in total

Fig. 11


IL6
1.0
0.8
0.6
0.4
0.2
0.0
- - +
0h 24h
CCL2
60
50
40
30
20
10
0
LPS (-)
LPS (+)
IL1B
50
40
30
20
10
0
TNF
20
15
10
5
0